靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期- |
/ Active, not recruiting临床1/2期 A Multi-center, Open-label, Phase 1/2a Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KAT-101 in Subjects With HCC
NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.
100 项与 Primocure Pharma, Inc. 相关的临床结果
0 项与 Primocure Pharma, Inc. 相关的专利(医药)
100 项与 Primocure Pharma, Inc. 相关的药物交易
100 项与 Primocure Pharma, Inc. 相关的转化医学